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The mu opioid receptor is a G-protein coupled receptor able to signal through the Gαi/o class of G-protein
and β-arrestin pathways, stimulating down-stream effector pathways. Signaling bias occurs when dif-
ferent receptor agonists lead to different signaling outcomes. Traditionally these have been studied using
end-point assays. Real-time cellular analysis platforms allow for the analysis of the holistic effects of
receptor activation as an integrated output. While this allows for different ligands to be compared ra-
pidly, the cellular mechanisms underlying the signal are not well described. Using an impedance based
system, the impedance responses for two opioid ligands, morphine and DAMGO were examined.
The impedance responses for these two agonists, while showing similar features, were distinct from
each other. Some of the mechanisms underlying the mu opioid receptor coupled impedance changes
were investigated. It was found that the response is a result of discrete cellular processes, including
G-protein signaling and protein kinase phosphorylation.
Crown Copyright & 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The mu opioid receptor (MOR) is a member of the opioid family of
receptors and the large G-protein coupled receptor (GPCR) super-
family. Activation of this receptor results in a GDP/GTP exchange at
speciﬁc G-proteins with the resulting release of the G-protein subunits
leading to stimulation of downstream effector pathways. Receptor
activation can also result in the recruitment of β-arrestin leading to
receptor internalisation and the activation of a G-protein independent
signaling pathway. Agonists can activate different pathway subsets
leading to signaling bias [1,2].
The opioid agonists [D-Ala2, NMe-Phe4, Gly-ol5]-enkephalin
(DAMGO) and morphine are both MOR agonists which have been
shown to exhibit bias in their signaling [3,4]. One measure of this bias
is the induction of receptor internalisation. In the majority of cell
types, treatment with DAMGO leads to internalisationwhile morphine
shows relatively less internalisation [5–8]. A second illustration of bias
is the observation that in β-arrestin2 knockout mice, morphine an-
algesia is enhanced while respiratory depression is reduced [9].
In addition to ligand bias changing the level at which pathways
can be activated, the outcomes of receptor stimulation can be inﬂu-
enced by type or state of a cell. There is also the possibility of un-
expected pathways being activated causing the full set of effects to beevier B.V. This is an open access a
protein coupled receptor; CI,
inese hamster ovary; FCS,
5]-enkephalin
ce.gov.aumissed [3,5,6,10,11]. A systemwith a read-out capturing thewhole cell
response to receptor activation will allow a holistic comparison of
agonists. Label-free real-time cellular analysis (RTCA) platforms allow
an approach naïve to the actual mechanisms activated but instead
capture an integrated whole-cell output. This can include cell pro-
cesses that have not previously been described [11,12].
One RTCA platform uses an impedance based assay, which
measures the change in impedance over time produced by cul-
tured cells grown on an array of interdigitated circuits on the base
of a 96-well microplate. This provides an output integrating the
whole cell signals that lead to a change in impedance resulting
from ligand stimulation. The assay is label-free and provides for a
real-time analysis of cell events [13,14]. This technique is starting
to be utilised to examine GPCR ligands with a goal of allowing an
unbiased method of classifying ligands into discrete pharmacolo-
gical categories and to give an indication of their signaling bias
[12,15]. Most of the underlying mechanisms that lead to ligand-
induced cellular morphological changes and a change in cellular
impedance are not well understood. A better understanding of
what cellular processes underlie impedance proﬁles will allow a
more conﬁdent assessment of compounds and the prediction of
their properties. This may have applications such as the screening
of compounds for desirable properties.
Here the impedance proﬁles generated by the opioid agonists
DAMGO and morphine were compared using Chinese Hamster Ovary
(CHO) cells stably overexpressing the MOR and some of the cellular
processes behind the impedance response were investigated. In par-
ticular the contribution of kinase signaling cascades to the responserticle under the CC BY-NC-ND license
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lead to distinct impedance proﬁles. The impedance response is the
result of discrete cellular processes which act in a time-dependent
manner. Part of this response is due to the contributions of the AKT1/
2/3 pathway, in the early stages of the response and the ERK1/2
pathway at later stages of the response.2. Material and methods
2.1. Cell culture
CHO cells stably expressing the human MOR were a gift from Dr.
Meritxell Canals [16]. Cell culture medium and foetal calf serum were
purchased from Gibco. Cells were maintained in DMEM medium
supplemented with 4.5 g/l D-Glucose and 10% foetal calf serum (FCS)
and incubated in a humidiﬁed incubator at 37 °C with 5% CO2.
2.2. Impedance measurement
The xCELLigence system (ACEA Biosciences, San Diego) was used to
measure changes in cellular impedance resulting from stimulation
with a ligand in 96-well E-Plates [13]. The E-Plate has electrode arrays
integrated into the bottom of the wells which allow for the mea-
surement of the impedance conferred by cells growing on this surface.
Changes in the measured impedance are deﬁned by a unit-less cell
index (CI). Prior to the addition of cells to the E-Plate, a CI measure-
ment was taken in the presence of 100 μl growth medium to de-
termine the background CI value for each well. This was subtracted
from the subsequent CI values as they were collected following cell
attachment. Cells were seeded at a density of 2104 cells/well and
cultured overnight in growth medium. After approximately 24 h, the
cell medium was replaced with serum free DMEM and the volume of
medium in the wells was adjusted to 180 μl for assays only requiring
ligand or 160 μl for assays requiring an additional treatment and in-
cubated overnight for approximately 16 h.
The E-plate was kept in the incubator for the duration of the ex-
periments. For the addition of compounds, E-Plate lid was replaced
with the RTCA Protector Shield 96 (allowing access to the wells whilst
the E-Plate is actively monitored in the cradle) and the E-Plate was
equilibrated for 30 min. Compounds were diluted in serum-free
medium to a 10 concentration, and added using an automated
multichannel pipette (20 μl /well). For agonist addition, the sampling
frequency was increased to the maximum possible with CI values
collected at 10 s intervals for a minimum period of 1 h.
For analysis, CI values were normalised by dividing by the cell
index at the time immediately prior to ligand addition (time¼0min).
Baseline corrections were carried out by subtracting the cell index
obtained from vehicle-treated cells. Between four and eight replicates
were used for each treatment per experiment.
2.3. Kinase activation assay
Cells were plated and grown in 96-well plates at a density of
4104 cells/well. The cells were cultured and treated with ligands as
described for the impedance measurement assay. ERK1/2 and AKT1/2/
3 phosphorylation were measured using the ERK1/2 (Thr202/Tyr204),
AKT1/2/3 Thr308 and AKT1/2/3 Ser473 AlphaScreen Sureﬁre kit
(Perkin Elmer). Cells were treated with 10 mM of either DAMGO or
morphine for varying periods of time required for the experiment,
then immediately lysed in 100 μl of the supplied lysis buffer with
shaking for 10 min at room temperature. Plates were then sealed and
stored at 20 °C. After thawing on ice, 5 μl were transferred to a 384-
well ProxiPlate (Perkin Elmer) to be used for the phosphorylation
assay as per the manufacturer's instructions.2.4. Data analysis
Graphing and analysis of results were performed using RTCA
software (v1.2.1.1002) provided by Roche Applied Science with the
xCELLigence System and Prism5 (GraphPad, CA, USA).
2.5. Materials
U0126, GSK2334470 and FB-124 were purchased from Tocris,
DAMGO [D-Ala2, NMe-Phe4, Gly-ol5]-enkephalin) and Morphine
sulphate were purchased from Sigma.3. Results and discussion
3.1. Impedance proﬁles
Real-time measurement of impedance results in a proﬁle which
represents the integration of multiple signal events stimulated by
receptor activation. The MOR is known to activate two signaling
pathways: Gαi/o/Gβɣ and β-arrestin. To determine the proﬁles re-
sulting from opioid receptor stimulation and to investigate whether
impedance measurements can distinguish between different agonists,
CHO cells stably overexpressing the human MOR were treated with
either DAMGO or Morphine.
The stimulation of cells using each agonist leads to a concentra-
tion-dependent, multi-featured, impedance response (Fig. 1). The
treatment of cells with either DAMGO or morphine resulted in proﬁles
that displayed broadly similar features, although each agonist dis-
played unique characteristics (Fig. 1A). The impedance proﬁles could
be divided into several phases. Stimulation using both agonists re-
sulted in a rapid rise in CI (rapid ascending phase), a peak (major
peak) and then an initial decay (ﬁrst decay). This was followed by a
“second ascending phase” and a second peak (minor peak). Finally a
“second decay” lead to a “plateau phase” inwhich the CI is maintained
at a level higher than the initial baseline.
The rapid ascending phase and major peak for each agonist
showed a high degree of similarity. In contrast, the region of the
proﬁle representing the minor peak showed differences. In particular,
the CI of this region was higher for cells stimulated by morphine
compared to DAMGO.
To demonstrate that this response was due to MOR activation, cells
were treated with the pan-antagonist naloxone (10 mM) prior to
agonist addition. Treatment with naloxone resulted in the complete
inhibition of the impedance response of both DAMGO and morphine
(Fig. 1B and C). Furthermore, the dose-response curve elicited by both
agonists was moved to the right with increasing concentrations of
Naloxone, indicating a competitive antagonism (data not shown).
Previous studies have examined the impedance response elicited
by the activation of several GPCR’s and have shown a diverse range of
impedance proﬁles. These include activation of the β2-Adrenergic
receptor, the niacin receptor GPR109A and the chemokine receptor
CXCR3 [12,15,17]. These reports showed that the stimulation of each
of these receptors resulted in a speciﬁc changes in cellular impedance
and that the response for an individual receptor was dependent on
the agonist used. The impedance proﬁles generated by the stimulation
of the MOR were distinct from those previously published, although
there were similarities with the two other Gi/o coupled receptors,
GPR109A and CXCR3. All three of these receptors have proﬁles which
contain a feature similar to the major peak shown here.
The impedance proﬁles were concentration-dependent with dif-
ferent features of the impedance proﬁle showing differential re-
sponses (Fig. 1D and E). This indicates that separate signaling events
were involved in the development of the impedance responses
over time. This was demonstrated by generating dose-response curves
for two of the features of the proﬁle; the major and minor peaks
Fig. 1. Ligand induced changes in cellular impedance mediated through the MOR. (A) Changes in cellular impedance in CHO-MOR cells were measured over time following
treatment with DAMGO or morphine. The phases of the response are indicted; rapid ascending phase (a), major peak (b), ﬁrst decay (c), minor peak (d), second decay (e) and
plateau phase (f). Cells were treated with 10 mM naloxone 30 min prior to the addition of (B) 10 mMDAMGO or (C) 10 mMmorphine. Cells were treated with (D) DAMGO or (E)
morphine at the concentrations indicated, concentration-response curves of the maximum Cell Index (CI) from the ﬁrst peak for (F) DAMGO and (G) morphine or the second
peak for (H) DAMGO and (I) morphine were generated. For (H), data points at Log Conc. 0 and 1 mM were not included in the curve ﬁtting. Cells were seeded at a density of
2104 cells/well and maintained at 37 °C, 5% CO2 for the duration of the experiment. Data presented is the mean of between ﬁve and eight independent experi-
ments7Standard deviation.
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showed a normal sigmoidal response with EC50s of 77.7 nM for the
major peak and 82.4 nM for the minor peak (Fig. 1G and I). In contrast
DAMGO treated cells produced an impedance proﬁle for which the
shape of the dose response curves varied at these different points
(Fig. 1F and H). The major peak behaved in a normal sigmoidal fashion
with an EC50 of 18.3 nM; the minor peak showed a biphasic response.
At DAMGO concentrations below 100 nM, a normal sigmoidal re-
sponse curve was seen (EC50 of 12.7 nM). At higher concentrations,
increases in the DAMGO concentration lead to a decrease in CI. This
indicates that there may be competing signals underlying the change
in impedance, the impedance proﬁle being the combined effect of all
of the pathways and processes that contribute to the change in the
cellular impedance.
To test whether the observed impedance response included un-
derlying mechanisms coupled to the G-protein pathway, the function
of the G-proteins was speciﬁcally inhibited using pertussis toxin (PTX),
which uncouples the receptor from Gαi/o proteins [18] and gallein,
which inhibits the interactions of Gβɣ with its substrates [19,20]. Sti-
mulation of PTX-pretreated cells with DAMGO and morphine resulted
in a loss of the impedance response (Fig. 2A and B). In contrast, the
gallein pre-treatment lead to major peaks reduced to 45% (SEM74.2)
and 38% (SEM78.2) that of non-treated cells, for DAMGO and mor-
phine respectively (Fig. 2C and D). The minor peak for both of the
treatments was reduced but still visible, while the plateau phase was
completely lost. These data suggest that the entire MOR impedance
signal is reliant on the presence of a functional Gαi/o. This includes the
β-arrestin mediated response. The recruitment of β-arrestin isFig. 2. Changes in opioid induced changes in cellular impedance are mediated by Gαi/o an
ml PTX and then treated with 10 mM (A) DAMGO or (B) morphine. Cells were treated wit
Cells were seeded at a density of 2104 cells/well and maintained at 37 °C, 5% CO2 for t
independent experiments7Standard deviation.stimulated by the phosphorylation of the receptor via G-protein re-
ceptor kinases (GRK), recruited to the receptor by the free Gβɣ [21].
3.2. Kinase phosphorylation
The activation of MOR is known to lead to the activation of MAPK
pathways. While ERK1/2 is the most widely described, other pathways
have also been implicated in the opioid response [22–24]. The acti-
vation of several MAPK, the NF-κB and AKT signaling pathways in
response to the opioid treatments were measured using Alphascreen
antibody-based assays. There was no evidence of the activation of p38,
JNK or NF-κB (data not shown), whereas ERK1/2 and AKT1/2/3 dis-
played phosphorylation in response to MOR activation in a time de-
pendent manner (Fig. 3).
Following both DAMGO and morphine treatments, the phosphor-
ylation of ERK1/2 was detected using an antibody binding to the
Threonine 202/Tyrosine 204 phosphorylated epitope. Phosphorylation
of ERK1/2 was detected after two minutes and peaked at ﬁve minutes
(Fig. 3A and D). The activation of the AKT1/2/3 pathway was in-
vestigated using two assays to detect either the phosphorylated
Threonine 308 (Thr308) or Serine 473 (Ser473) sites of AKT1, 2 and 3.
The phosphorylation at both of these sites occurred rapidly in cells
treated with DAMGO or morphine. For cells treated with DAMGO, AKT
phosphorylation peaked at two minutes and rapidly decreased (Fig. 3B
and C). For cells treated with morphine, the peak in AKT phosphor-
ylation at both sites occurred at ﬁve minutes and was sustained for
longer (Fig. 3E and F).d Gβɣ. CHO-MOR cells were grown overnight in the presence or absence of 100 ng/
h 100 mM gallein for 1 h and then Treated with 10 mM (C) DAMGO or (D) morphine.
he duration of the experiment. Data presented is the mean of between four and six
Fig. 3. Time dependent ligand induced protein phosphorylation in CHO-MOR cells. Cells were treated with 10 mM DAMGO and assayed for ERK1/2 phosphorylation (A),
AKT1/2/3 phosphorylation at Thr308 (B) or AKT1/2/3 phosphorylation at Ser473 (C). Cells were treated with 10 mM morphine and assayed for ERK1/2 phosphorylation (D),
AKT1/2/3 phosphorylation at Thr308 (E) or AKT1/2/3 phosphorylation at Ser473 (F). Data is normalised to the response induced by 10% FCS at 10 min and expressed as the
mean7Standard deviation of three independent experiments.
Fig. 4. The inhibition of kinase pathway components results in discreet effects on the cellular impedance. CHO-MOR cells were treated with inhibitors for 30 min before the
addition of 10 mM ligand. Cells treated with 10 mM FPA124, 5 mM U0126 or 10 mM GSK2334470 were treated with DAMGO (A–C) or morphine (D–F). Cells were seeded at a
density of 2104 cells/well and maintained at 37 °C, 5% CO2 for the duration of the experiment. Data presented is the mean of between four and six independent ex-
periments7Standard deviation.
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The contribution of these protein phosphorylation pathways to
the impedance proﬁles was examined using three chemical in-
hibitors to disrupt the signaling; U0126 to block ERK1/2 phos-
phorylation, FPA124 to directly inhibit AKT1/2/3 and GSK2334470,
an inhibitor of 3-phosphoinositide-dependent protein kinase 1
(PDK1) [25–27]. PDK1 represents a signal pathway branch point,
with the ability to phosphorylate MEK (the kinase responsible for
ERK phosphorylation) on Ser222 and Ser226 [28,29] and AKT on
Thr308 [30,31].
When FPA124-treated cells were stimulated with either DAMGO or
morphine, the effect on the impedance response was predominantly
on the amplitude of the major peak and the plateau phase (Fig. 4A and
D). The major peak was reduced to 64% and 70% of the maximum CI
for DAMGO and morphine respectively while the plateau phase was
lost. There was no effect on the slope ascending phase or the sec-
ondary peak. In contrast, the pre-treatment of cells with U0126 re-
sulted in an agonist-stimulated impedance proﬁle showing only a
minor effect on the amplitude of the major peak (more than 90% of
maximum CI), little effect on the plateau phase but an complete loss of
the second peak (Fig. 4B and E). Inhibition of PDK1 with GSK2334470
resulted in an impedance response that resembled a combination of
the two previous proﬁles (Fig. 4C and F). The amplitude of the major
peak compared to the uninhibited cells was reduced to 57% for
DAMGO and 56% for morphine and the secondary peak and plateau
phase for both was completely lost.
These data suggest that the ERK1/2 and AKT1/2/3 pathways largely
contributed to separate features of the impedance response. This
contribution aligns with the temporal activation of the two proteins.
The initial major peak occurs between 2 and 3min and is most af-
fected by inhibition of the AKT pathway. The ERK pathway provides
only a minor contribution to the major peak, but is signiﬁcant in the
formation of the minor peak which occurs at approximately 10 min.
These results are consistent with the timing of AKT and ERK phos-
phorylation. There is some evidence (data not shown) that there may
be subtle differences in the timing of these impedance proﬁle features
between the two agonists which bears further investigation.
In the impedance proﬁles presented, the second minor peak is
mainly the result of the activation of the ERK pathway. This region
also provides the major difference between the impedance proﬁles
generated by the two agonists. This implies that, although both
agonists lead to ERK1/2 phosphorylation, there are differences in
the mechanism by which this is achieved. GPCR coupled ERK1/2
phosphorylation can be stimulated via two mechanisms, G-protein
or β-arrestin coupled [26]. A major contributor to receptor bias
described for GPCRs has been shown to be differences in the ac-
tivation of these two pathways [32,33]. Furthermore, the activa-
tion of ERK1/2 is further complicated by the ability of ERK1/2 to
function either in the cytosol or translocate to the nucleus [26,34].
It is likely that the different ERK related impedance signatures
have a basis in the different levels of coupling to one of the ERK
pathways [3]. The impedance proﬁles show both a difference in
both the shape of the curve and the dose-response at this region.
Morphine stimulation results in a peak with a higher CI and a
sigmoidal dose-response curve while DAMGO stimulation leads to
a peak with a lower peak CI and dose-response curve with two
phases. This minor peak has also been observed to be more vari-
able in both shape and relative amplitude than any of the other
phases of the proﬁles (data not shown). This indicates the possi-
bility of dynamic cellular processes, including the recruitment of
interacting proteins such as regulators of G protein signaling
(RGS), having an inﬂuence on the impedance response [3].
This report describes the application of an electrical impedance
RTCA assay to study the MORmediated signaling stimulated by morp-
hine and DAMGO. While this work focused on two kinasephosphorylation pathways, it is clear that there are other mechanisms
which contribute to the impedance proﬁles. Further effort will eluci-
date the additional mechanisms that lead to changes in impedance. It
is likely that factors such as receptor internalisation andmodulation of
ion channels will be contributors. The study demonstrated that dis-
tinct impedance proﬁles can result from different opioid agonists
acting on the same cell type. This opens up the possibility for opioid
compounds to be grouped into pharmacological classes based on their
impedance proﬁles and for this system to be used to predict signal
bias and agonist properties.Acknowledgment
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